Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics - Top-Institutions - MDSpire

Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics

  • By

  • Fuliang Li

  • Hongmei Li

  • Dulguun Juramt

  • Kai Kou

  • Frank Tacke

  • Lanlan Chen

  • July 2, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hepatology
    • Gastroenterology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Hepatology
    • Gastroenterology

Original Source(s)

Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics

  • by Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen

  • July 2, 2026

Related Content

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis

Impact of meal frequency on gastroesophageal reflux disease following laparoscopic sleeve gastrectomy

Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications